![Janssen Demonstrates Strong Commitment to Advancing Science of Inflammatory Bowel Disease with Robust Selection of Data Presentations at 14th Congress of ECCO | Business Wire Janssen Demonstrates Strong Commitment to Advancing Science of Inflammatory Bowel Disease with Robust Selection of Data Presentations at 14th Congress of ECCO | Business Wire](https://www.sttinfo.fi/data/images/00301/cc734d3d-9449-43af-910f-effb76d21937-w_300_h_100.png)
Janssen Demonstrates Strong Commitment to Advancing Science of Inflammatory Bowel Disease with Robust Selection of Data Presentations at 14th Congress of ECCO | Business Wire
![Frontiers | An Update for Pharmacologists on New Treatment Options for Inflammatory Bowel Disease: The Clinicians' Perspective Frontiers | An Update for Pharmacologists on New Treatment Options for Inflammatory Bowel Disease: The Clinicians' Perspective](https://www.frontiersin.org/files/Articles/655054/fphar-12-655054-HTML-r1/image_m/fphar-12-655054-g001.jpg)
Frontiers | An Update for Pharmacologists on New Treatment Options for Inflammatory Bowel Disease: The Clinicians' Perspective
![PDF) Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: A cross-sectional, observational study | Peter Bampton - Academia.edu PDF) Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: A cross-sectional, observational study | Peter Bampton - Academia.edu](https://0.academia-photos.com/attachment_thumbnails/69213294/mini_magick20210908-7738-1io5vii.png?1631134388)
PDF) Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: A cross-sectional, observational study | Peter Bampton - Academia.edu
![PDF) Dose-optimization for loss-of-response to vedolizumab - pharmacokinetics and immune mechanisms | published in Journal of Crohn s and Colitis PDF) Dose-optimization for loss-of-response to vedolizumab - pharmacokinetics and immune mechanisms | published in Journal of Crohn s and Colitis](https://i1.rgstatic.net/publication/350787153_Dose-optimization_for_loss-of-response_to_vedolizumab_-_pharmacokinetics_and_immune_mechanisms/links/609003f9458515d315f36c79/largepreview.png)
PDF) Dose-optimization for loss-of-response to vedolizumab - pharmacokinetics and immune mechanisms | published in Journal of Crohn s and Colitis
![PDF) P721 Psychological care is needed and welcomed by patients with inflammatory bowel disease under routine care PDF) P721 Psychological care is needed and welcomed by patients with inflammatory bowel disease under routine care](https://i1.rgstatic.net/publication/322889795_P721_Psychological_care_is_needed_and_welcomed_by_patients_with_inflammatory_bowel_disease_under_routine_care/links/5d4a17c64585153e59413e28/largepreview.png)